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S U M M A R Y
Background: There is evidence that aminoglycosides given in a single daily dose (once daily dose, ODD)
are as effective and safe as multiple daily doses (MDD). However, the published pharmacokinetic and
pharmacodynamic data are overly representative of pediatric populations in Europe and the USA, and
not representative of low or middle-income countries such as Costa Rica, in which the patient population
might differ from those in higher income settings.
Methods: A double-blind, randomized clinical trial of the efﬁcacy and safety of ODD vs. MDD amikacin
therapy was conducted for children aged 2–12 years with an intraoperative diagnosis of perforated
appendicitis. One hundred patients were randomized following a one-to-one randomization to receive
either amikacin 7.5 mg/kg every 8 h (MDD) or 22.5 mg/kg as a single dose (ODD). Patients in both groups
were given clindamycin 10 mg/kg every 6 h. Efﬁcacy was evaluated by the occurrence of intra-
abdominal abscesses, documented by abdominal ultrasound, and therapeutic failure. Safety was
determined by the presence of renal or cochlear toxicity.
Results: Fifty patients were enrolled in each group. There were no statistically signiﬁcant differences in
the incidence of intra-abdominal abscesses or therapeutic failures, or in the occurrence of cochlear or
renal toxicity, between the MDD and ODD treatment groups.
Conclusions: In this patient population of Costa Rican children with perforated appendicitis, we found
that amikacin ODD is as safe and effective as the MDD regimen. This could have implications for national
health systems such as that in Costa Rica, as ODD is presumably a more economic option and may reduce
the cost of antibiotic treatment in patients with perforated appendicitis. This would need to be
conﬁrmed through an economic analysis, which is outside the purview of this paper.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Aminoglycosides are commonly used for the treatment of
children with perforated appendicitis, despite their potential to
cause ototoxicity and nephrotoxicity.1,2 However, there is still
debate, even in clinical settings where resources are not limited, as
to whether these antibiotics should be given in multiple daily
doses (MDD) or as a single daily dose (once daily dose, ODD). ODD
has been shown to achieve higher peak plasma concentrations
with relatively undetectable trough concentrations, and thus to§ Trial registration: Estudio 229-08-04-00017. Comparacio´n de la eﬁcacia y
seguridad de la amikacina, administracio´n u´nica diaria contra tres dosis diarias en
pacientes pedia´tricos con apendicitis aguda perforada.
* Corresponding author. Tel.: +506 22552239; fax: +506 22552239.
E-mail address: vperezh@hnn.sa.cr (V. Pe´rez).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.04.012exert a high concentration-dependent bactericidal activity, greater
post-antibiotic effect, lower risk of adaptive resistance, and
reduced accumulation in the inner ear and renal proximal
tubules.3–5 Recent systematic reviews of the efﬁcacy and safety
of giving aminoglycosides as an ODD to children and neonates have
concluded that ODD is preferable to MDD, because ODD both
minimizes costs and simpliﬁes administration while remaining
efﬁcacious and safe.6,7 However, most empirical data in these
reviews are derived from well developed American and European
clinical settings in pediatric populations.8,9 As a result the
promulgated standard of care may not be the same for other
populations with potential metabolic differences in drug handling.
As the healthcare systems in low- and middle- income countries
continue to develop, it is critical that clinical investigation follows
that of the countries that generally dominate the peer reviewed
literature so that appropriate and cost-effective patient care
evolves.ses. Published by Elsevier Ltd. All rights reserved.
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comparing the two amikacin dosing regimens in the pediatric
population,10–13 we found only one other prospective study in the
English language literature conducted in children with peritoni-
tis.14 As most systematic reviews use English search terms and
peer review literature only, the above-mentioned populations are
not represented in existing analysis. Thus, to further build the
available empirical pharmacodynamic, pharmacokinetic, and
outcome data, we undertook a prospective, double-blind, con-
trolled study to compare the effectiveness and safety of ODD vs.
MDD of amikacin in patients with perforated appendicitis in a
patient population in a middle-income country, Costa Rica, for
which little empirical data exist.
2. Methods
The protocol for this trial and supporting CONSORT checklist are
available as supporting information (see Supplementary Informa-
tion, appendices 1 and 2).
2.1. Participants
This was a prospective, randomized, double-blind, single-center
study. The patient population consisted of 100 children aged
between 2 and 12 years, with a diagnosis of perforated appendicitis
in the operating room at the Department of General Surgery,
National Children’s Hospital in San Jose´, Costa Rica. Fifty patients
were assigned to each group following a one-to-one randomization.
Exclusion criteria included: known allergy to aminoglycosides,
known impaired renal function, known hearing loss or vestibular
disease, neutropenia, cystic ﬁbrosis, neuromuscular disease, con-
comitant administration of furosemide or other nephrotoxic drugs,
and history of treatment with aminoglycosides in the preceding 2
weeks. Informed consent was obtained from parents or legal
guardians of the patients prior to enrollment.
2.2. Ethics
Original approval for this study protocol (attached in Supple-
mentary Information, appendix 2) was granted by the ethics
committees of the National Children’s Hospital, COIBI-CCSS and
Universidad de Costa Rica.
2.3. Study endpoints
Primary endpoints: For efﬁcacy the objective was to determine
if there was a statistically signiﬁcant difference between the two
therapeutic groups regarding the development of intra-abdominal
abscesses and treatment failures. For safety the objective was to
determine if there was a statistically signiﬁcant difference
between the two therapeutic groups regarding the development
of nephrotoxicity and ototoxicity.
Secondary endpoints: We also assessed if there was a
statistically signiﬁcant difference between the two therapeutic
groups of patients with respect to body temperature, leukocyte
count, C-reactive protein (CRP) serum concentration, and hospital
stay.
2.4. Study protocol
One hundred patients were assigned to either regimen using
computer-generated random numbers kept by the pharmacists; the
blinding was not broken until the end of the study. An interim
analysis was done when 40 patients were enrolled in the study to
look for signiﬁcant differences in efﬁcacy and safety between the
two groups. At that point there were no differences. Using acomputer-generated randomization program (http://www.rando-
mizer.org), the patients were randomized into either the ODD arm,
to receive 22.5 mg/kg every 24 h, or the MDD arm, to receive 7.5
mg/kg every 8 h; only the pharmacist was aware of the randomiza-
tion assignment. The amikacin dose was calculated according to
body weight in all cases and was not adjusted in any case.
VP (ﬁrst author) was responsible for the random allocation
sequence, the surgeon who performed the surgery (usually the
pediatric surgical resident) enrolled the participants, and the
pharmacist assigned the subjects to the intervention. Patients and
care providers were kept blind to the intervention. Patients assigned
to MDD received amikacin sulfate 7.5 mg/kg of body weight every
8 h as a 20-min infusion, without exceeding 500 mg per dose.
Patients assigned to ODD received amikacin sulfate 22.5 mg/kg of
body weight once daily over the same infusion time as MDD and not
exceeding 1.5 g per dose. In the ODD group, the ﬁrst amikacin dose
was followed by two further doses of saline every 8 h in a volume
equal to that of the corresponding amikacin dose. The color of the
solution was the same and only the pharmacist who prepared the
solution knew the intervention group. All study patients also
received clindamycin 10 mg/kg, administered as an intravenous
infusion over 20 min every 6 h. Patients with perforated appendicitis
and localized peritonitis were given antibiotics for a minimum of 5
days and those with generalized peritonitis received antibiotics for
at least 7 days. Antibiotic treatment beyond 7 days was administered
to patients with a documented intra-abdominal abscess deﬁned by
the presence of one or more collections in the pre-rectal space, right
iliac fossa, mid-abdomen, or retrovesical area, visualized by
abdominal ultrasound.
2.5. Cultures
Samples of peritoneal exudates were obtained from all patients
and sent for aerobic bacterial cultures. They were plated onto blood
and MacConkey agar and only the predominant organism from
each culture was reported. The minimum inhibitory concentration
(MIC) for amikacin was determined for any bacteria grown from an
intraoperative sampling, and the maximum concentration (Cmax)/
MIC ratio was calculated for each isolate.15 Anaerobic cultures
were not performed.
2.6. Amikacin serum concentrations
Amikacin peak and trough serum concentrations were mea-
sured on days 2, 4, 6, and 8 of therapy. After sampling, plasma was
separated and frozen at 70 8C until processed (within 1 month).
Amikacin concentrations were determined by ﬂuorescence polari-
zation immunoassay (Abbott Tax; sensitivity 0.8 mg/ml).
2.7. Renal function assessment
The serum creatinine concentration was determined prior to
the start of therapy with amikacin and every 48 h thereafter until
its discontinuation. Any abnormal value was followed until its
return to the normal range according to age. Amikacin-related
renal toxicity was deﬁned as an increase in serum creatinine
0.4 mg/dl from the basal post-rehydration value before the ﬁrst
dose was administered.
2.8. Cochlear function
Cochlear function was assessed according to the age of the
patient. Children younger than 4 years of age were screened
through oto-acoustic emissions (OAE-DP), immittance, and free-
ﬁeld audiometry (behavioral observational audiometry, BOA).
Children over the age of 4 years were assessed with conventional
V. Pe´rez et al. / International Journal of Infectious Diseases 15 (2011) e569–e575 e571behavioral play audiometry and immittance.16 BOA and play
audiometry were considered normal with thresholds 20 dB at
0.5, 1, 2, 4, 8 kHz. OAE were assessed considering the presence or
absence of distortion products in the frequencies of 2, 3, 4, and 5 kHz.
Absence or reduction in the noise-tone difference (NTD) with respect
to baseline for the emissions was considered abnormal. All patients
were tested by the same person (JM) who was unaware of the
randomization. Patients had baseline tests done on day 3 of
admission to the study and at a follow-up examination 6 weeks after
discharge. Ototoxicity or cochlear damage was deﬁned by sensori-
neural hearing impairment predominant in the frequencies between
2 and 8 kHz. A drop of 10–15 dB hearing levels (HL) at one or more
frequencies, usually at 2, 4, 6, and 8 kHz, with respect to baseline
values was considered abnormal.17
All patients underwent abdominal ultrasound on days 5 and 10
after surgery in order to rule out intra-abdominal abscesses. The
person who performed the ultrasound was unaware of the
therapeutic regimen of each patient. Clinical success was deter-
mined by the absence of intra-abdominal collections on days 5 to 10
of therapy and an axillary body temperature 37.5 8C for at least two
consecutive days, leukocyte count below 12  109 cells/l, and serum
CRP 40 mg/l. Treatment failure was deﬁned by persistence of an
intra-abdominal abscess after 10 days of effective antibiotic therapy
accompanied by fever, leukocyte count above 12  109 cells/l, and a
serum CRP > 40 mg/l. Amikacin and clindamycin were stopped in
these patients and they were successfully treated with the
combination of metronidazole and ceftazidime for 7 days.
2.9. Statistical analysis
Approximately 800 patients are admitted to our hospital with a
diagnosis of acute appendicitis every year. Between 300 and 350 of
these children are diagnosed with perforated appendicitis, and the
incidence of intra-abdominal abscesses has been estimated to be
between 25% and 30% in our institution in the past. We calculated
that a sample size of 100 patients would allow us to detect a
reduction in the incidence of intra-abdominal abscess from 30% to
5%, assuming a power of 80% and a cut-off for statistical
signiﬁcance of 0.05.
The unpaired Student’s t-test for parametric data was used to
compare body temperature, leukocyte count, CRP, serum creati-
nine, Cmax/MIC, and duration of hospital stay. A two-tailed Fisher’s
exact test for categorical data was used to compare intra-
abdominal abscess and treatment failure. Test results were
calculated using SPSS version 6.0 (SPSS Inc., Chicago, IL, USA)
and STATA MP version 11 (StataCorp., College Station, TX, USA).
3. Results
Fifty children were enrolled into each arm of the study between
April 2005 and February 2006. The trial was closed when 100Table 1
Characteristics of the study patients
ODD group (n = 50) 
Age (months) 94  36 
Gender 
Male 26 (52) 
Female 24 (48) 
Weight (kg) 26.9  11.2 
Height (cm) 122.3  18.4 
Temperature (8C) 38.6  0.68 
Leukocyte count (109/l) 18.005  6.123 
CRP (mg/l) 147  91 
Serum creatinine (mg/dl) 0.58  0.16 
Results are given as mean  SD or n (%).
ODD, once daily dosing; MDD, multiple daily dosing; CRP, C-reactive protein; SD, standarsubjects were enrolled. There were no differences in demographic
or clinical characteristics between the MDD and ODD groups (Table
1). Twenty-one patients in each group had perforated appendicitis
with localized peritonitis and 29 in each group had generalized
peritonitis. There were no deaths during the study period. Three
patients were withdrawn from the study within the ﬁrst 72 h after
randomization at the parents’ request; the outcomes of these
subjects were excluded from the analysis.
No statistically signiﬁcant differences in daily body tempera-
ture between the two groups were documented. Seventy-one
percent of the patients in the MDD group were afebrile by day 4 vs.
70% in the ODD group, with mean axillary temperatures of
37.3  0.67 8C and 37.3  0.7 8C, respectively (p = 0.7). Eighty-eight
percent of the patients in the MDD group were afebrile by day 7 vs.
89% in the ODD group (p = 0.8) (Figure 1).
Leukocyte counts were similar in the two treatment groups on
days 4 and 8 of treatment. Mean counts on day 4 in the MDD and
ODD groups were 11.179  3.625  109 cells/l and
10.385  3.515  109 cells/l, respectively (p = 0.2). On day 8 they
were 14.300  4.381  109 cells/l and 14.421  4.713  109 cells/l,
respectively (p = 0.9) (Figure 2).
CRP concentrations in both groups were similar throughout the
study. On day 4 of treatment the mean CRP concentrations were
64  41 mg/l in the MDD group vs. 74  49 mg/L in the ODD group
(p = 0.3), and on day 8 they were 40  39 mg/l in the MDD group vs.
46  21 mg/l in the ODD group (p = 0.7) (Figure 3).
Overall 11 patients developed intra-abdominal abscesses for an
incidence of 11%; this included eight patients in the MDD arm and
three in the ODD arm (relative risk (RR) 2.67, 95% conﬁdence
interval (CI) 0.75–9.47; p = 0.11). Six patients had unresolved
peritoneal abscesses after completing 10 days of amikacin and
clindamycin; all of them were successfully treated with a
combination of metronidazole and cefotaxime and none of them
required surgical drainage. Five of these patients belonged to the
MDD group and one to the ODD group (RR 5.0, 95% CI 0.6–41;
p = 0.09). There were no differences between the study groups with
respect to hospital stay; the MDD group had a mean hospital stay
of 178.7  72.7 h vs. 169  61.3 h for the ODD group (p = 0.7).
There was no evidence of renal toxicity in any of the patients.
On day 4 of therapy, patients in the MDD and ODD groups had a
mean serum creatinine value of 0.5  0.11 mg/dl (p = 0.9). On day 8,
the values were 0.5  0.17 mg/dl for the ODD group and 0.6  0.1
mg/dl for the MDD group (p = 0.2) (Figure 4).
All patients enrolled in the study had normal baseline auditory
function tests. Eighty-one patients, 40 in the MDD group and 41 in
the ODD group, had follow-up examinations. Two patients, one
from each therapeutic group, had a mild (20–39 dB) decrease in
auditory acuity.
Regarding amikacin serum levels, the mean trough amikacin
concentrations were signiﬁcantly lower in the ODD regimen on
days 2, 4, and 6. In this group none of the patients had troughMDD group (n = 50) p-Value
98  33 0.6
0.5
30 (60)
20 (40)
30.6  12.6 0.12
126  16.9 0.29
38.5  0.77 0.3
17.172  5.731 0.47
151  85 0.82
0.6  0.13 0.5
d deviation.
Figure 1. Median and IQR for temperature for the ODD and MDD group, Day 1 to Day 10.
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MDD regimen had toxic trough amikacin concentrations: one had
13.1 mg/ml on day 4 and the other 17.8 mg/ml on day 8. Both
patients had normal renal function according to serum creatinine:
the ﬁrst one had a trough amikacin concentration of 2.7 mg/ml
2 days later when she ﬁnished treatment; the second patientFigure 2. Median and IQR of leukocyte counts forcompleted 10 days of amikacin and levels were not taken that day
because he was discharged early. Mean peak concentrations were
higher in the ODD regimen on days 2, 4, 6, and 8; none of the
patients in this group had amikacin concentrations below 30
mg/ml (Figure 5). Cmax/MIC was calculated for 73 patients who had
positive cultures from the peritoneal cavity, 37 in the MDD group the ODD and MDD group, Day 1 to Day 10.
Figure 3. Median and IQR of C-reactive protein for the ODD and MDD group, Day 1 to Day 10.
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Cmax/MIC value of 9  3.6 vs. 21  4.7 mg for those on the ODD
regimen (p < 0.01).
Patients from both therapeutic groups were bacteriologically
comparable. Peritoneal samples from 37 patients in the MDD
group had bacterial growth: Escherichia coli (n = 36) and Pseudo-
monas aeruginosa (n = 1). The samples from the other 13 patients
had sterile aerobic cultures. Thirty-six patients in the ODD group
had bacterial growth from their peritoneal samples: E. coli (n = 30),
P. aeruginosa (n = 3), Klebsiella pneumoniae (n = 2), and Citrobacter
freundii (n = 1); 14 of the patients had sterile aerobic cultures. E. coliFigure 4. Median and IQR of serum creatinine forisolates had a MIC for amikacin of 2 mg/ml in 63 patients and of
4 mg/ml in three patients. P. aeruginosa isolates had a MIC for
amikacin of 2 mg/ml in three patients and of 8 mg/ml in one
patient. K. pneumoniae and C. freundii isolates had a MIC for
amikacin of 2 mg/ml.
4. Discussion
This study, carried out in pediatric patients with perforated
appendicitis, provides additional evidence for the efﬁcacy and
safety of ODD of aminoglycosides compared to MDD. We chose to the ODD and MDD group, Day 1 to Day 10.
Figure 5. Median and IQR of amikacin serum levels for the ODD and MDD group, Day 2 to Day 8.
V. Pe´rez et al. / International Journal of Infectious Diseases 15 (2011) e569–e575e574conduct the study in children with perforated appendicitis because
it is the most common abdominal surgical emergency in pediatric
patients,18 and since all patients with a ruptured appendix are
undoubtedly infected, it is possible to evaluate the true efﬁcacy of
each regimen.
Our study did not ﬁnd any signiﬁcant differences in the clinical
evolution between the two groups of patients, i.e., body
temperature, leukocyte count, and serum CRP concentration.
The most clinically pertinent ﬁnding of this study was the lower
incidence of intra-abdominal abscesses in patients on the ODD
regimen. This might be explained by the fact that these patients
had signiﬁcantly higher Cmax/MIC and it is well known that the
bactericidal action of aminoglycosides is concentration- and area
under the curve (AUC)-dependent.19 Patients on the MDD
regimen had a higher rate of therapeutic failures in accordance
with previous studies that have demonstrated a direct relation-
ship between outcome and pharmacokinetic–pharmacodynamic
(PK/PD) parameters.20–23
Of critical consideration is that most health centers in
developing countries cannot afford to measure aminoglycoside
serum concentrations on a regular basis due to limited resources.
Although our study did not show a statistically signiﬁcant
difference between the two regimens with regard to efﬁcacy,
there was a trend towards a lower incidence of intra-abdominal
abscess formation and therapeutic failure with the ODD regimen.
An overly ambitious effect size estimation may have led to
inadequate power for our study, and may explain our failure to
attain statistical signiﬁcance in our primary endpoint analyses.
Our results do suggest that this is a safe regimen. Although some
clinicans24,25 consider intraoperative abdominal cavity cultures
of no value in patients with perforated appendicitis, we routinely
perform aerobic cultures from all samples obtained during
surgery. In this study, the two groups of patients were
comparable with respect to the aerobic isolates and their
susceptibility patterns to aminoglycosides, namely gentamicin
and amikacin.Also of clinical and standard of care importance, we found that
patients in the MDD group had mean peak serum amikacin levels
that did not reach therapeutic concentrations, contrary to our
previous assumption; this ﬁnding can be explained by the fact that
patients with peritonitis have a much greater volume of
distribution.9 At our hospital we have routinely treated these
patients with amikacin at a dose of 7.5 mg/kg administered every
8 h with the aim of reaching peak levels of at least 25 mg/ml and
trough levels of less than 5 mg/ml.26 Also of note is that two
patients with normal renal function according to serum creatinine
in the MDD group had trough amikacin levels above the maximum
accepted concentration
While some debate exists on the ideal method for monitoring
renal toxicity in patients treated with aminoglycosides, in our
study we could not demonstrate any case of primary nephrotoxi-
city in patients as deﬁned by Kumana and Yuen,27 neither could we
ﬁnd any signiﬁcant difference when we compared serum creati-
nine levels between the two groups of patients.
Our study, like others,28 showed a similar low incidence of
ototoxicity in the two therapeutic groups. Although the exact
mechanism of this toxic effect is unknown, it has been suggested
that ototoxicity occurs mostly in patients with impaired renal
function and with the concomitant use of other nephrotoxic drugs
that elevate aminoglycoside serum concentrations and enhance
their cochlear toxicity.29 None of our patients had these predis-
posing conditions, which may account for the low incidence of
ototoxicity in our trial.
To summarize, the results of this trial show that ODD of amikacin
is an effective and equally safe regimen in comparison to MDD. Also,
the ODD regimen provides more appropriate PK/PD parameters than
the MDD. This study was not designed to address a cost–beneﬁt
analysis of MDD vs. ODD. However, one could hypothesize that the
ODD regimen might reduce the cost of antibiotic treatment in
patients with perforated appendicitis, based on the fact that this
regimen implies a reduction in the cost of preparation, administra-
tion, and the total amount of drug used for each patient.30
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